花旗:升君實生物(1877.HK)目標價至80港元 為生物科技行業首選股
花旗發表報告稱,君實生物(1877.HK)治療新冠狀病毒的創新型藥物在全球推廣試驗進展順利,突顯出公司的研發效率,上調其目標價60%至80港元,並列為生物科技行業的首選股。
花旗指,中和抗體較可能引起ADE(抗體依賴增強效應)及潛在病毒突變風險的疫苗更好,可能是治療新冠病毒最理想的方法,而君實與禮來公司在中國地區外達成合作,無疑是對公司創新平台及研發標準的認可,在中國生物技術領域具有象徵性意義。
該行認為,市場之前對PD-1銷售預期低,股價對國家醫保藥品降價的敏感性下降,因此增加營銷及指標加速擴張或會帶來股價上行的意外驚喜;此外,潛在納入滬港通的機會亦提高其流動性。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.